SCHEMBL4783322

SCHEMBL4783322

CN1CCN(c2n[nH]c3ccc(C(=O)NCc4ccc(Cl)cc4)cc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
MAPK10 P53779 2/20 0.49
MAPK8 P45983 1/20 0.49
MAPK3 P27361 3/20 0.48
MAPK1 P28482 3/20 0.48
KDM1A O60341 1/20 0.47
HDAC1 Q13547 1/20 0.47
POLB P06746 1/20 0.47
RXFP1 Q9HBX9 1/20 0.45
AURKA O14965 2/20 0.45
NTRK1 P04629 1/20 0.45
INSR P06213 1/20 0.45
IGF1R P08069 1/20 0.45
AURKB Q96GD4 1/20 0.45
ALK Q9UM73 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
FLT3 P36888 1/20 0.44
B3GNT2 Q9NY97 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784235 0.92 KMT2A (0.51) KMT2AMAPK10MAPK8KDM1AHDAC1
SCHEMBL4781301 0.82 AURKA (0.54) KMT2AMAPK10MAPK3MAPK1AURKA
SCHEMBL4783741 0.81 KIT (0.52) KMT2AMAPK10MAPK8SMN1; SMN2FLT3
SCHEMBL4783423 0.80 KIT (0.51) KMT2AMAPK10MAPK8KDM1AHDAC1
SCHEMBL4783835 0.80 DDR1 (0.53) MAPK8MAPK1HDAC1
SCHEMBL5945710 0.78 CNR2 (0.54) KMT2AKDM1AHDAC1AURKANTRK1
SCHEMBL4784112 0.78 ALDH1A1 (0.54) KMT2AMAPK10MAPK8MAPK1ALK
SCHEMBL4783980 0.77 CNR1 (0.48) MAPK10MAPK1AURKANTRK1INSR
SCHEMBL9778488 0.77 HRH4 (0.53) MAPK1POLBCNR1
SCHEMBL4783798 0.76 CNR1 (0.48) MAPK10MAPK1AURKANTRK1INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US claimed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO claimed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS MCHR1, MCHR2, MC1R KMT2A 3487/4885MAPK10 3802/4885MAPK8 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.